Table 4.
Hazard Ratios for Stroke in HIV-Stratified Models
| HIV (N= 2255) | Control (N=32423) | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Female gender | 0.97 (0.50-1.89) | 0.921 | 0.54 (0.46-0.65) | <0.001 |
| Age | 1.06 (1.03-1.09) | <0.001 | 1.07 (1.07-1.08) | <0.001 |
| White race (vs. all others) | 1.40 (0.80-2.46) | 0.235 | 0.99 (0.85-1.15) | 0.846 |
| Hypertension | 0.79 (0.44-1.45) | 0.451 | 1.30 (1.09-1.55) | 0.003 |
| Diabetes | 0.59 (0.28-1.23) | 0.159 | 1.17 (0.98-1.39) | 0.077 |
| Dyslipidemia | 0.99 (0.55-1.80) | 0.987 | 0.75 (0.63-0.88) | 0.001 |
| Smoking (ever vs. never) | 0.83 (0.49-1.40) | 0.483 | 1.29 (1.11-1.49) | 0.001 |
| Structural heart disease | 1.24 (0.62-2.44) | 0.544 | 2.25 (1.87-2.69) | <0.001 |
| Endocarditis | 0.91 (0.27-3.04) | 0.881 | 2.18 (1.56-3.04) | <0.001 |
| Atrial fibrillation | 3.15 (1.26-7.87) | 0.014 | 1.24 (0.96-1.60) | 0.100 |
| Aspirin use | 1.73 (0.91-3.28) | 0.096 | 0.70 (0.58-0.83) | <0.001 |
| Warfarin use | 0.70 (0.26-1.89) | 0.484 | 0.71 (0.54-0.93) | 0.012 |
| NRTI use | 1.19 (0.51-2.79) | 0.681 | N/A | N/A |
| NNRTI use | 0.38 (0.19-0.76) | 0.006 | N/A | N/A |
| PI use | 0.63 (0.30-1.33) | 0.226 | N/A | N/A |
| CD4 count (cells/mm3)* | 0.97 (0.90-1.05) | 0.477 | N/A | N/A |
| HIV RNA (copies/ml)† | 1.10 (1.04-1.17) | 0.001 | N/A | N/A |
| CNS infection/malignancy | 2.75 (1.26-6.03) | 0.011 | N/A | N/A |
Abbreviations: HR = hazard ratio; NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; CNS = central nervous system.
*
CD4 cell count nadir expressed in increments of 50.
†
HIV RNA expressed as log value of continuous variable.